Cargando…

Correction: CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021761/ https://www.ncbi.nlm.nih.gov/pubmed/35444063 http://dx.doi.org/10.1136/jitc-2021-003289corr1

Ejemplares similares

CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment
por: Seyfrid, Mathieu, et al.
Publicado: (2022)

UPAR AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN RECURRENT GLIOBLASTOMA
por: Maich, William, et al.
Publicado: (2023)

Correction: Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer
por: Jia, Keren, et al.
Publicado: (2023)

CD70 in Thymic Squamous Cell Carcinoma: Potential Diagnostic Markers and Immunotherapeutic Targets
por: Kashima, Jumpei, et al.
Publicado: (2022)

Correction: Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds
Publicado: (2021)

Correction: Cytosolic Hsp70 as a biomarker to predict clinical outcome in patients with glioblastoma
por: Lämmer, Friederike, et al.
Publicado: (2021)

Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies
por: Pombo Antunes, Ana Rita, et al.
Publicado: (2020)

Correction: GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
Publicado: (2021)

Correction: Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1
Publicado: (2023)

Immunotherapeutic Advancements for Glioblastoma
por: Ampie, Leonel, et al.
Publicado: (2015)

Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

Deciphering the Labyrinthine System of the Immune Microenvironment in Recurrent Glioblastoma: Recent Original Advances and Lessons from Clinical Immunotherapeutic Approaches
por: Anghileri, Elena, et al.
Publicado: (2021)

Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer
por: Jacobs, Julie, et al.
Publicado: (2015)

Immunotherapeutic Approaches for Glioblastoma Treatment
por: Yaghi, Nasser K., et al.
Publicado: (2022)

New Immunotherapeutic Approaches for Glioblastoma
por: Vázquez Cervantes, Gustavo Ignacio, et al.
Publicado: (2021)

Correction: Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors
por: Pires, Eusebio S., et al.
Publicado: (2017)

Correction to: Lactate modulates microglia polarization via IGFBP6 expression and remodels tumor microenvironment in glioblastoma
por: Longhitano, Lucia, et al.
Publicado: (2022)

Correction: Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma
por: Lai, Jinzhi, et al.
Publicado: (2022)

Author Correction: Liposomal delivery of azithromycin enhances its immunotherapeutic efficacy and reduces toxicity in myocardial infarction
por: Al‑Darraji, Ahmed, et al.
Publicado: (2021)

Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma
por: Liu, Zhenjiang, et al.
Publicado: (2017)

Syringeable immunotherapeutic nanogel reshapes tumor microenvironment and prevents tumor metastasis and recurrence
por: Song, Chanyoung, et al.
Publicado: (2019)

Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity
por: Angelova, Assia L., et al.
Publicado: (2017)

Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
por: Wang, Pengju, et al.
Publicado: (2018)

Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations
por: Niedbała, Marcin, et al.
Publicado: (2022)

Current Immunotherapeutic Strategies for the Treatment of Glioblastoma
por: Dapash, Mark, et al.
Publicado: (2021)

Single-Cell Transcriptomics of Glioblastoma Reveals a Unique Tumor Microenvironment and Potential Immunotherapeutic Target Against Tumor-Associated Macrophage
por: Cui, Xiaoteng, et al.
Publicado: (2021)

The immunosuppressive role of indoleamine 2, 3-dioxygenase in glioblastoma: mechanism of action and immunotherapeutic strategies
por: Hosseinalizadeh, Hamed, et al.
Publicado: (2022)

Immune microenvironment of medulloblastoma: The association between its molecular subgroups and potential targeted immunotherapeutic receptors
por: Kurdi, Maher, et al.
Publicado: (2023)

Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma
por: Hänsch, Lena, et al.
Publicado: (2023)

Correction: CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
Publicado: (2021)

Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies
por: Genoud, Vassilis, et al.
Publicado: (2021)

Correction: Functional Analysis of Hsp70 Inhibitors
por: Schlecht, Rainer, et al.
Publicado: (2013)

Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
por: Buqué, Aitziber, et al.
Publicado: (2020)

Correction: Suppressive effects of the obese tumor microenvironment on CD8 T cell infiltration and effector function
por: Dyck, Lydia, et al.
Publicado: (2022)

Correction to: Aspinall S, et al. Human Vaccines and Immunotherapeutics Volume 8, Issue 8; pp.1109–18
por: Aspinall, Sanet, et al.
Publicado: (2013)

The role of CMV in glioblastoma and implications for immunotherapeutic strategies
por: Rahman, Maryam, et al.
Publicado: (2018)

Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas
por: Nesseler, Jean Philippe, et al.
Publicado: (2018)

Cytokines in type 1 diabetes: mechanisms of action and immunotherapeutic targets
por: Lu, Jingli, et al.
Publicado: (2020)

Ultrasound-targeted microbubble destruction remodels tumour microenvironment to improve immunotherapeutic effect
por: Liu, Senbo, et al.
Publicado: (2022)

Correction: Glioblastoma and glioblastoma stem cells are dependent on functional MTH1
por: Pudelko, Linda, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i2ik07evh626fqke28v33qe02h